Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis

Experimental Dermatology

Volumn 15, Issue 5, 2006, Pages 381-386

  Paquet, Phillipe ^a   Kaveri, S ^b   Jacob, E ^b,c   Pirson, J ^b,c   Quatresooz, P ^a   Pierard G E ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b INSERM   (France)

^c QUEEN ASTRID MILITARY HOSPITAL   (Belgium)

Author keywords

Immunoglobulins; Toxic epidermal necrolysis

Indexed keywords

ALLOPURINOL; AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFEPIME; HUMAN IMMUNOGLOBULIN; IBUPROFEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INDAPAMIDE; NAPROXEN; OXACILLIN; PHENYTOIN; SERTRALINE; TELITHROMYCIN; VANCOMYCIN; IMMUNOGLOBULIN;

ADULT; ARTICLE; BLISTER; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REGIMEN; EPIDERMIS; FEMALE; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEPOSITION; IMMUNOHISTOCHEMISTRY; MALE; NEPHELOMETRY; SKIN BIOPSY; TOXIC EPIDERMAL NECROLYSIS; ADOLESCENT; AGED; BLOOD; BODY FLUID; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; SKIN;

ADOLESCENT; ADULT; AGED; BLISTER; BODY FLUIDS; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; SKIN;

EID: 33745256243     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.0906-6705.2006.00426.x     Document Type: Article

References (23)

1. Paquet P, Piérard G E, Quatresooz P. Novel treatments for drug-induced toxic epidermal necrolysis (Lyell's syndrome). Int Arch Allergy Immunol 2005: 136: 205-216.
2. Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 2003: 162: 1515-1520.
3. Nassif A, Bensussan A, Boumsell L et al. Epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004: 114: 1209-1215.
4. Paquet P, Nikkels A, Arrese J E, Vanderkelen A, Piérard G E. Macrophages and tumor necrosis factor-alpha in toxic epidermal necrolysis. Arch Dermatol 1994: 130: 605-608.
5. Herndon D N. Toxic epidermal necrolysis: A systemic and dermatologic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids. J Am Coll Surg 1995: 180: 340-342.
6. Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998: 282: 490-493.
7. Kazatchkine M D, Kaveri S V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001: 345: 747-755.
8. Stella M, Cassano P, Bollero D, Clemente A, Giorio G. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: Our experience. Dermatology 2001: 203: 45-49.
9. Paquet P, Jacob E, Damas P, Piérard G E. Treatment of drug-induced toxic epidermal necrolysis (Lyell's syndrome) with intravenous human immunoglobulins. Burns 2001: 27: 652-655.
10. Tristani-Firouzi P, Petersen M, Saffle J R, Morris S, Zone J. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 2002: 47: 548-552.
11. Prins C, Kerdel F A, Padilla R S, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins. Arch Dermatol 2003: 139: 26-32.
12. Bachot N, Revuz J, Roujeau J C. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2003: 139: 33-36.
13. Trent J T, Kirsner R S, Romanelli P, Kerdel F A. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN. Arch Dermatol 2003: 139: 39-43.
14. Bastuji-Garin S, Rzany B, Stern R S, Shear N H, Naldi L, Roujeau J C. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993: 129: 92-96.
15. Dati F, Schumann G, Thomas L, et al. Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP reference material (CRM470). Eur J Clin Chem Clin Biochem 1996: 34: 517-520.
16. Arrese J E, Ben Mosbah T, Piérard-Franchimont C, Deleixhe-Mauhin F, Piérard G E. Importancia diagnostica de los depositos de inmunoglobulinas y complemento en afectiones cutaneas: Nuevas tecnicas y perspectivas. Med Cutan Ibero Lat Am 1993: 21: 131-135.
17. Quatresooz P, Fumal I, Willemaers V, Cornil F, Piérard G E. Diffuse dermal angiomatosis: Undescribed pattern of immunoglobulin and complement deposits in two cases. Am J Dermatopathol (in press).
18. Gouteux-Frezzotti D, Bolard F, Ramon P H, Steenhouwer F. Etude de différents critères biologiques permettant de distinguer les exsudats pleuraux des transsudats. Rev Pneumol Clin 2002: 58: 11-16.
19. Persson C G A, Erjefalt J S, Greiff L, et al. Plasma-derived proteins in airway defence, disease and repair of epithelial injury. Eur Respir J 1998: 11: 958-970.
20. Lerner L H, Qureshi A A, Reddy B V, Lerner E A. Nitric oxide synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome. J Invest Dermatol 2000: 114: 196-199.
21. Perez A C, Khawaja A M, Page C P, Paul W. Persistence of effects of nitric oxide synthase inhibitors: Comparisons on blood flow and plasma exudation in guinea pig skin. Eur J Pharmacol 1997: 330: 241-246.
22. Stein K, Schlappner O, Heaton C, Decherd J. Demonstration of basal cell immunofluorescences in drug-induced toxic epidermal necrolysis. Br J Dermatol 1972: 86: 246-252.
23. Hensen E J, Claas F H J, Vermeer B J. Drug-dependent binding of circulating antibodies in drug-induced toxic epidermal necrolysis. Lancet 1981: Ii: 151-152.